Sun Pharma Advanced Research Company Limited, a biopharmaceutical firm, is involved in the research and development of pharmaceutical products both in India and globally. Its focus lies in creating new chemical and biological entities, as well as reformulated products, with therapeutic emphasis on areas such as oncology, neurodegeneration, ophthalmology, and dermatology. The company's product portfolio includes Elepsia, a levetiracetam formulation for epilepsy treatment, and Xelpros, a latanoprost ophthalmic emulsion used to treat open-angle glaucoma or ocular hypertension.
Furthermore, Sun Pharma Advanced Research Company Limited is actively working on several projects, including SDN-037, a difluprednate formulation in phase 3 clinical trial for treating inflammation and pain post-ocular surgery; PDP-716 in phase 3 clinical trial for glaucoma treatment; phenobarbital sodium for neonatal seizures; Vodobatinib (SCO-088) successfully completing part A of Phase 1 study for resistant chronic myelogenous leukemia; Vodobatinib (SCC-138) in phase 2 clinical trial for Parkinson's disease; SCD-044 in phase 2 clinical trial for psoriasis and atopic dermatitis treatment; and SCO-120 in phase 1 clinical trial for hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer.
Sun Pharma Advanced Research Company Limited has entered collaboration agreements with Bioprojet SCR for developing an S1P receptor 1 agonist targeting autoimmune disorders, and with HitGen Ltd. to identify small molecule leads for specific targets of interest. Established in 2006, the company is headquartered in Mumbai, India, and operates as a subsidiary of Shanghvi Finance Private Limited.
Furthermore, Sun Pharma Advanced Research Company Limited is actively working on several projects, including SDN-037, a difluprednate formulation in phase 3 clinical trial for treating inflammation and pain post-ocular surgery; PDP-716 in phase 3 clinical trial for glaucoma treatment; phenobarbital sodium for neonatal seizures; Vodobatinib (SCO-088) successfully completing part A of Phase 1 study for resistant chronic myelogenous leukemia; Vodobatinib (SCC-138) in phase 2 clinical trial for Parkinson's disease; SCD-044 in phase 2 clinical trial for psoriasis and atopic dermatitis treatment; and SCO-120 in phase 1 clinical trial for hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer.
Sun Pharma Advanced Research Company Limited has entered collaboration agreements with Bioprojet SCR for developing an S1P receptor 1 agonist targeting autoimmune disorders, and with HitGen Ltd. to identify small molecule leads for specific targets of interest. Established in 2006, the company is headquartered in Mumbai, India, and operates as a subsidiary of Shanghvi Finance Private Limited.
